2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-163154
    JJC8-091 1627576-76-4 98%
    JJC8-091 is a potent dopamine transporter (DAT) inhibitor with Ki values of 230, 97800 nM for DAT, SERT, respectively. JJC8-091 has the potential for the research of psychostimulant use disorders (PSUD).
    JJC8-091
  • HY-163155
    RDS03-94 2324108-96-3 98%
    RDS03-94 is a dopamine transporter (DAT) inhibitor. RDS03-94 reduces hERG/DAT ratio.
    RDS03-94
  • HY-163156
    JJC12-009 98%
    JJC12-009 is a dopamine transporter (DAT) inhibitor, with a Ki of 5.45 nM.
    JJC12-009
  • HY-163162
    Anhydro-Ouabain 3029806-33-2 98%
    Anhydro-Ouabain (compound 20) is a cardiotonic steroid which shows anti-inflammatory and neuroprotective activities and thus can be used in neurological research.
    Anhydro-Ouabain
  • HY-163175
    BChE-IN-24 98%
    BChE-IN-24 is a selective and reversible BChE inhibitor with an IC50 of 9 nM. BChE-IN-24 can be used for the research of Alzheimer’s disease and related neurodegenerative disorders.
    BChE-IN-24
  • HY-163189
    c-ABL-IN-6 98%
    c-ABL-IN-6 (compound A6) is a c-ABL inhibitor with IC50 value of 16.6 nM. c-ABL-IN-6 displays higher neuroprotective effects against SH-SY5Y cell death induced by MPP+ (HY-W008719). c-ABL-IN-6 can be used for the research of neurodegenerative disorder.
    c-ABL-IN-6
  • HY-163202
    MAGL-IN-13 98%
    MAGL-IN-13 (compound (3R, 4S) - 5v) is a selective, irreversible inhibitor for MAGL,with IC50 values of 0.026, 0.021 and 0.24 nM for mMAGL, hMAGL and rMAGL, respectively. MAGL-IN-13 can penetrant blood brain barrier. .
    MAGL-IN-13
  • HY-163205
    VU6067416 3027515-24-5 98%
    VU6067416 is a potent and brain-penetrant 5-HT2A agonist with an EC50 of 189 nM.
    VU6067416
  • HY-163207
    sEH/HDAC6-IN-1 2847838-67-7 98%
    sEH/HDAC6-IN-1 (compound M9) is a selective, orally active dual inhibitor for sEH and HDAC6, with IC50s of 2 nM, 0.72 nM and 5 nM, for human sEH, murine sEH and HDAC6, respectively. sEH/HDAC6-IN-1 reveals analgesic and anti-inflammatory effects.
    sEH/HDAC6-IN-1
  • HY-163276
    OX2R-IN-2 98%
    OX2R-IN-2 (compound 63c) is an agonist for orexin receptor type 2 (OX2R) with EC50 of 339 nM. OX2R-IN-2 is able to cross the blood-brain barrier and exhibits no cytotoxicity in cells
    OX2R-IN-2
  • HY-163280
    JGB-1-155 3011930-28-9 98%
    JGB-1-155 is a positive allosteric modulators (N-PAMs), which enhances the activity of nicotinamide phosphoribosyltransferase NAMPT with EC50 of 3.29 μM. JGB-1-155 counteracts the oxidative stress, through upregulating the NAD+ in THP-1 human monocytes. JGB-1-155 attenuates TNFα-induced ROS in HT-22 cells .
    JGB-1-155
  • HY-163283
    6′-Methyl paeonol 6540-66-5 98%
    6’-Methyl paeonol is a paeonol derivative, which inihibits abnormal depolarizations and reduces the Amyloid β-induced ERK phosphorylation. 6’-Methyl paeonol exhibits alleviating activity against Alzheimer’s Disease.
    6′-Methyl paeonol
  • HY-163320
    AChE/Aβ-IN-5 181114-32-9 98%
    AChE/Aβ-IN-5 (compound AV-2) is a bifunctional inhibitor that targets AChE and auto-induced Aβ (Amyloid-β) aggregation. AChE/Aβ-IN-5 can significantly improve scopolamine- and Aβ-induced cognitive impairment in mice.
    AChE/Aβ-IN-5
  • HY-163322
    MAO-A inhibitor 2 98%
    MAO-A inhibitor 2 (compound HT4) is a monoamine oxidase A (MAO-A) inhibitor with an IC50 of 14.3 µM. MAO-A inhibitor 2 shows a less effect on MAO-B (IC50 of 106 µM) and shows almost ineffective on xanthine oxidase (XO). MAO-A inhibitor 2 can be used for the neurodegenerative disorders and oxidative stress research.
    MAO-A inhibitor 2
  • HY-163327
    pFBC 98%
    pFBC ([18F]pEBC) is a covalent CLIP-tag radiotracer for detection of viral reporter gene transfer in the murine brain. pFBC can be used in neurobiological research.
    pFBC
  • HY-163329
    BCH-HSP-C01 98%
    BCH-HSP-C01 is a lead compound that restores AP-4-dependent protein trafficking in neuronal models of adapter protein complex 4 (AP-4)-associated hereditary spastic paraplegia. BCH-HSP-C01 can be used for the research of autophagy-associated diseases.
    BCH-HSP-C01
  • HY-163345
    5-HT7R antagonist 2 1448808-50-1 98%
    5-HT7R antagonist 2 (compound 4h) is a 5-HT7R antagonist that antagonizes the G protein and β-arrestin signaling pathways, with a Ki of 67 nM, the IC50 values in cAMP and Tango tests were 2.59 μM and 39.57 μM, respectively. 5-HT7R antagonist 2 has an effect on neurogenesis and can reduce repetitive behaviors related to autism spectrum disorder (ASD) and restore neurogenesis of ASD impairment.
    5-HT7R antagonist 2
  • HY-163349
    TUG-2099 98%
    TUG-2099 (compound 4s) is a potent GPR84 agonist with the EC50 of 0.3 nM. TUG-2099 can be used for study of Alzheimer’s disease, atherosclerosis, cancer, and so an.
    TUG-2099
  • HY-163370
    HIF-1α-IN-7 3026685-76-4 98%
    HIF-1α-IN-7 (Compound D13) is a potent HIF-1α inhibitor. HIF-1α-IN-7 has neuroprotective activity. HIF-1α-IN-7 can be used in Alzheimer's disease research.
    HIF-1α-IN-7
  • HY-163380
    CA/MAO-B-IN-1 98.34%
    CA/MAO-B-IN-1 (Compound 78) is a dual inhibitor for human brain carbonic anhydrases (CA) and Monoamine Oxidase-B (MAO-B), with IC50s of 8.8 and 7.0 nM, respectively. CA/MAO-B-IN-1 reveals a human oral absorption of 71.9% through in silico prediction.
    CA/MAO-B-IN-1
Cat. No. Product Name / Synonyms Application Reactivity